NCT05468242
Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
Notable Enrollment target: 60 to 116v3 Show 7 more changesShow less
- Primary and study completion dates: Feb 1, 2024 to Dec 30, 2024
- Primary endpoints: 2 to 1
- Eligibility criteria shortened, about 3 words
- Start date: Feb 1, 2022 to Jan 1, 2022
- Interventions: Antivascular therapy concurrent with radiotherapy (Drug), Bevacizumab (Drug), Chemotherapy concurrent with radiotherapy (Drug), Neoadjuvant… to Bevacizumab (Drug), Neoadjuvant chemo-immunotherapy (Drug), Radiotherapy (Radiation), Tislelizumab (Drug)
- Secondary endpoints: 3 to 4
- Study title shortened, about 4 words
- Minor Secondary endpoints: details revised at 3 of 3 entriesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression free survival
Timeframe: 2-year
Secondary (4)
Overall survival
Adverse Event
Health-related Quality of Life
Objective response rate
Arms and interventions
Neoadjuvant Chemotherapy Plus Tislelizumab + BevacizumabExperimental
Patients in experimental group will receive Tislelizumab consolidation (200 mg/q3w) after the neoadjuvant chemotherapy plus Tislelizumab + Bevacizumab and concurrent chemoradiotherapy.
Neoadjuvant Chemotherapy Plus TislelizumabActive comparator
Patients in this group will receive Tislelizumab consolidation (200 mg/q3w) after the neoadjuvant chemotherapy plus Tislelizumab and concurrent chemoradiotherapy.
Drugs: Neoadjuvant chemo-immunotherapy, Bevacizumab, Tislelizumab
Radiation: Radiotherapy
Sites
1 site in 1 country
- Sun Yat-sen UniversityGuangzhou, China